###begin article-title 0
###xml 30 35 <span type="species:ncbi:9606">Child</span>
###xml 36 39 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
CCR5 Haplotypes and Mother-to-Child HIV Transmission in Malawi
###end article-title 0
###begin p 1
Conceived and designed the experiments: SM SR VM MM DK. Performed the experiments: VM DK MB. Analyzed the data: SM KN BP. Contributed reagents/materials/analysis tools: PZ KN. Wrote the paper: SM SR PZ BP.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 85 88 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
CCR5 and CCR2 gene polymorphisms (SNPs) have been associated with protection against HIV transmission in adults and with delayed progression to AIDS. The CCR5 Delta32 deletion and SNP -2459G are associated with reduced expression of the CCR5 protein.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 40 46 <span type="species:ncbi:9606">infant</span>
###xml 71 74 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 85 90 <span type="species:ncbi:9606">child</span>
###xml 141 148 <span type="species:ncbi:9606">infants</span>
###xml 162 165 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 175 180 <span type="species:ncbi:9606">women</span>
###xml 726 731 <span type="species:ncbi:9606">child</span>
We investigated the association between infant CCR2/CCR5 diplotype and HIV mother to child transmission (MTCT) in Malawi. Blood samples from infants (n = 552) of HIV positive women who received nevirapine were genotyped using a post-PCR multiplex ligase detection reaction and haplotypes were identified based on 8 CCR2/CCR5 SNPs and the open reading frame 32 base pair deletion. Following verification of Hardy-Weinberg equilibrium, log linear regression was performed to examine the association between mutations and MTCT. Overall, protection against MTCT was weakly associated with two CCR5 SNPs, -2459G (Risk ratio [RR], 0.78; confidence interval [CI], 0.54-1.12), and the linked CCR5 -2135T (RR, 0.78; CI, 0.54-1.13). No child carried the CCR5 Delta32 SNP. Maternal Viral Load (MVL) was found to be an effect measure modifier. Among mothers with low MVL, statistically significant protection against MTCT was observed for -2459G (RR, 0.50; CI, 0.27-0.91), and -2135T (RR, 0.51; CI, 0.28-0.92). Statistically significant protection was not found at high MVL.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 133 136 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Results from this study suggest that CCR5 SNPs -2459G and -2135T associated with reduced receptor expression protect against MTCT of HIV at low MVLs, whereas high MVLs may over-ride differences in coreceptor availability.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 124 127 124 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-UNAIDS1">[1]</xref>
###xml 253 261 253 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in utero</italic>
###xml 315 318 315 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Bertolli1">[2]</xref>
###xml 320 323 320 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Rouzioux1">[3]</xref>
###xml 21 29 <span type="species:ncbi:9606">children</span>
###xml 57 62 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 98 103 <span type="species:ncbi:9606">child</span>
###xml 143 151 <span type="species:ncbi:9606">children</span>
An estimated 600,000 children per year are infected with HIV-1, the majority of them by mother-to-child transmission (MTCT) [1]. Most of these children live in sub-Saharan Africa, where access to methods of preventing MTCT is still rare. MTCT can occur in utero, during labor and delivery, or through breastfeeding [2], [3].
###end p 9
###begin p 10
###xml 357 360 357 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-ArenzanaSeisdedos1">[4]</xref>
###xml 21 29 <span type="species:ncbi:9606">children</span>
###xml 80 85 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 128 133 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 159 162 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 306 311 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
There is evidence in children and adults that naturally occurring variations in HIV-1/chemokine receptors influence the risk of HIV-1 transmission and rate of HIV/AIDS disease progression. Genetic variations in chemokine receptor 5 (CCR5) and chemokine receptor 2 (CCR2) have been the focus of many recent HIV-1 transmission and disease progression studies [4].
###end p 10
###begin p 11
###xml 104 107 104 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Choe1">[5]</xref>
###xml 109 112 109 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Deng1">[6]</xref>
###xml 114 117 114 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Doranz1">[7]</xref>
###xml 119 122 119 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Dragic1">[8]</xref>
###xml 124 127 124 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Alkhatib1">[9]</xref>
###xml 301 305 297 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Dean1">[10]</xref>
###xml 307 311 303 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Huang1">[11]</xref>
###xml 313 317 309 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Liu1">[12]</xref>
###xml 319 323 315 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Samson1">[13]</xref>
###xml 325 329 321 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Zimmerman1">[14]</xref>
###xml 414 418 410 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Benkirane1">[15]</xref>
###xml 578 582 570 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Clegg1">[16]</xref>
###xml 584 588 576 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Knudsen1">[17]</xref>
###xml 590 594 582 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Kostrikis1">[18]</xref>
###xml 596 600 588 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-McDermott1">[19]</xref>
###xml 602 606 594 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Tang1">[20]</xref>
###xml 679 683 671 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Salkowitz1">[21]</xref>
###xml 685 689 677 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Hladik1">[22]</xref>
###xml 818 822 810 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Kostrikis2">[23]</xref>
###xml 903 907 895 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Kostrikis2">[23]</xref>
###xml 909 913 901 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Anzala1">[24]</xref>
###xml 915 919 907 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Easterbrook1">[25]</xref>
###xml 921 925 913 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-EugenOlsen1">[26]</xref>
###xml 927 931 919 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Gonzalez1">[27]</xref>
###xml 933 937 925 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Schinkel1">[28]</xref>
###xml 34 37 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 98 103 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Chemokine receptor 5 (CCR5) is an HIV co-receptor utilized by macrophage-tropic, or R5 strains of HIV-1 [5], [6], [7], [8], [9]. Homozygosity for a 32 base pair deletion (Delta32) in the open reading frame (ORF) has been shown to confer almost complete resistance to infection by R5 strains in adults [10], [11], [12], [13], [14]. This mutation has also been shown to be associated with reduced expression of CCR5 [15]. Similarly, several CCR5 promoter SNPs, principally -2459A-->G and -2135C-->T have been associated with decreased transmission or disease progression outcomes [16], [17], [18], [19], [20] as well as decreased infection and susceptibility to infection in vitro [21], [22]. A valine to isoleucine substitution at codon 64 in the CCR2b gene, in linkage disequilibrium with regions of the CCR5 promoter [23], is associated with delayed disease progression in some, though not all studies [23], [24], [25], [26], [27], [28].
###end p 11
###begin p 12
###xml 141 145 141 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Mummidi1">[29]</xref>
###xml 147 155 147 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000838-g001">Figure 1</xref>
###xml 78 83 <span type="species:ncbi:9606">human</span>
Because the various mutations in CCR2 and CCR5 are in linkage disequilibrium, human haplotypes A-E, F*1, F*2, G*1, and G*2 have been defined [29] (Figure 1).
###end p 12
###begin title 13
CCR2/CCR5 Haplotypes and abridged phylogenetic tree.
###end title 13
###begin p 14
Haplotypes were constructed based on the evolution of linked CCR2 and CCR5 mutations, including a valine to isoleucine substitution at codon 64 in the CCR2b gene (CCR2-64I), CCR5 mutations -2733A-->G, -2554 G-->T, -2459A-->G, -2135C-->T, -2132C-->T, -2086A-->G, -1835C-->T, and the delta-32 deletion in the open reading frame of CCR5 (CCR5-ORF).
###end p 14
###begin p 15
###xml 162 166 162 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Kostrikis1">[18]</xref>
###xml 224 228 224 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Mangano1">[30]</xref>
###xml 394 398 390 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Ometto1">[31]</xref>
###xml 351 359 <span type="species:ncbi:9606">children</span>
Only a handful of studies have looked at CCR5 haplotype and susceptibility to MTCT. Haplotype D homozygosity was associated with increased susceptibility to MTCT [18] as was both haplotype E homozyogosity and heterozygosity [30]. A more recent study found a protective effect against MTCT of homozygosity for the G2 haplotype (Delta32) but only among children of mothers with lower viral loads [31]. Thus, CCR5 haplotypes appear to affect susceptibility to MTCT in a complex manner.
###end p 15
###begin p 16
###xml 268 272 268 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Mwapasa1">[32]</xref>
###xml 28 31 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 41 46 <span type="species:ncbi:9606">women</span>
###xml 156 161 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 240 247 <span type="species:ncbi:9606">infants</span>
###xml 255 258 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 394 399 <span type="species:ncbi:9606">child</span>
###xml 419 422 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Here we studied a cohort of HIV positive women in Malawi to determine whether individual CCR2/CCR5 haplotypes are associated with perinatal transmission of HIV-1. Although mothers received nevirapine prior to delivery, approximately 20% of infants became HIV infected [32]. We further investigated whether there was an interaction between maternal viral load and polymorphisms in determining a child's relative risk of HIV acquisition.
###end p 16
###begin title 17
Methods
###end title 17
###begin title 18
Data Collection
###end title 18
###begin p 19
###xml 105 109 105 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Mwapasa2">[33]</xref>
###xml 359 363 359 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Mwapasa2">[33]</xref>
###xml 830 834 830 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Mwapasa2">[33]</xref>
###xml 413 418 <span type="species:ncbi:9606">women</span>
###xml 500 505 <span type="species:ncbi:9606">Women</span>
###xml 653 656 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 666 671 <span type="species:ncbi:9606">women</span>
###xml 726 729 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 764 769 <span type="species:ncbi:9606">women</span>
###xml 822 829 <span type="species:ncbi:50278|species:ncbi:153742">quinine</span>
###xml 836 843 <span type="species:ncbi:9606">Infants</span>
###xml 847 850 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 915 921 <span type="species:ncbi:9606">Infant</span>
###xml 938 941 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We conducted ancillary data analysis of a larger completed cohort study described by Mwapasa et al, 2004 [33]. The original cohort study was recruited from December 2000 to June 2002 at Queen Elizabeth Central Hospital, Blanytre, Malawi. The estimated population in Blantyre at the time of the study was 950,000, 40% of whom lived in urban or periurban areas [33]. Study eligibility was determined among pregnant women attending the antenatal ward, after completing medical and obstetric assessment. Women in active labor, living outside of Blantyre, less than 15 years of age, with hypertension, or with altered consciousness were excluded. Consenting HIV positive women received nevirapine prior to delivery as well as post-HIV test counseling. Malaria infected women were treated with sulfadoxine pyrimethamine or oral quinine [33]. Infants of HIV-infected mothers received a single dose of nevirapine at birth. Infant whole blood for HIV testing and genotyping was collected at birth and at follow-up visits scheduled 6 and 12 weeks after delivery.
###end p 19
###begin title 20
Laboratory Methods
###end title 20
###begin p 21
###xml 372 376 368 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Mwapasa2">[33]</xref>
###xml 9 12 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 54 57 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 180 186 <span type="species:ncbi:9606">Infant</span>
###xml 297 303 <span type="species:ncbi:9606">Infant</span>
###xml 304 307 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 387 392 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 464 469 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Maternal HIV status was established by two concordant HIV rapid tests (Determine(R), Abbott Laboratories, Abbott Park, IL, USA, and Serocard(R), Trinity BioTech, Dublin, Ireland). Infant and maternal DNA was extracted from whole blood using the QiAMP DNA Extraction Kit (Qiagen, Helden, Germany). Infant HIV status at birth, 6 and 12 weeks was determined by real time PCR [33]. Maternal HIV-1 RNA concentration measurements were performed using the Roche Amplicor HIV-1 Monitor(R) Test, version 1.5 (Roche Diagnostics, Branchburg, NJ). CD4 count was determined by FACSCount (BD, San Jose, CA).
###end p 21
###begin p 22
###xml 127 131 123 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Salkowitz2">[34]</xref>
###xml 365 369 361 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Bruse1">[35]</xref>
###xml 133 139 <span type="species:ncbi:9606">Infant</span>
Detection of the CCR5 ORF Delta32 by analysis of amplified fragment length polymorphisms was performed as previously described [34]. Infant genotype at CCR2-64V/I and CCR5 promoter SNPs -2733A/G, -2554G/T, -2459A/G, -2135C/T, -2132C/T, -2086A/G, -1835C/T was determined using a multiplex ligase detection reaction (LDR) based method with flow cytometric technology [35]. Briefly, a 1,118 base pair fragment of the CCR5 promoter containing the seven promoter SNPs and a 327 base pair fragment in the CCR2 ORF were PCR-amplified. The amplicon was then probed with two primers, an upstream allele specific primer with a unique 24 nucleotide FlexMAPtrade markTAG sequence extension (Luminex(R) Corporation, Austin, TX) and a downstream 5' phosphorylated/3' biotinylated conserved sequence primer. Following allele specific hybridization, the primers were ligated. Ligation products were hybridized with fluorescent bead-labelled anti-TAG probes, and the 3' biotin group labeled with phycoerythrin (PE). Mean fluorescence intensity of the allele-specific LDR:bead-labelled anti-TAG hybrid complexes was read on a BioPlex array reader (Bio-Rad Laboratories, Hercules, CA) into allele specific channels and used to determine genotypes (Bruse et al in preparation).
###end p 22
###begin p 23
###xml 210 214 210 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Mwapasa2">[33]</xref>
The original cohort study was approved by the Malawi College of Medicine Research and Ethics Committee and by the review boards at the University of Michigan and the University of North Carolina at Chapel Hill [33].
###end p 23
###begin title 24
Statistical Analysis
###end title 24
###begin p 25
CCR2/CCR5 SNPs were tested for Hardy-Weinberg Equilibrium and Fisher's Exact Test was used to estimate pair-wise associations between MTCT and mutations or haplotypes, as well as the association between MTCT and maternal CD4 count, maternal viral load, maternal age, peripheral malaria parasite density, and mode of delivery (vaginal or caesarian).
###end p 25
###begin p 26
Log-linear regression was performed to determine the association between each SNP and haplotype with MTCT. Due to the rarity of some SNPs, 3 category genotypes (heterozygotes and homozygous variant genotypes compared separately to the homozygous wild type referent genotype) as well as the presence/absence of the variant allele (hetero- and homozygous variants combined as one group and compared to the referent) were examined. Regression models were adjusted for all covariates used in the imputation of log MVL. Adjustment for multiple comparisons was made using the Bonferroni correction. Because log MVL is a strong determinant of MTCT, effect measure modification by MVL was examined by comparing results at below and above the median value of log MVL (4.57).
###end p 26
###begin p 27
The Likelihood Ratio Test (LRT) was used to test for homogeneity of the associations between MTCT and SNP/haplotype, across MVL categories.
###end p 27
###begin p 28
These statistical analyses were performed in SAS version 9.1.3 (SAS, Cary, NC).
###end p 28
###begin p 29
###xml 35 42 <span type="species:ncbi:9606">infants</span>
###xml 113 116 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 138 145 <span type="species:ncbi:9606">infants</span>
###xml 260 267 <span type="species:ncbi:9606">infants</span>
###xml 360 363 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 411 414 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Three MTCT outcomes were examined: infants infected via intrauterine transmission (IU), identified by a positive HIV PCR result at birth; infants infected via intrapartum transmission (IP), identified by first positive PCR result at six weeks after birth; and infants infected via peripartum transmission (PP), identified at week 12 of follow-up. A cumulative HIV transmission variable was created to represent HIV infection at any follow-up time in the study. To assess the consistency of our findings, sensitivity analyses were performed by modeling the outcomes IU, IP, PP, and cumulative transmission, in four separate models.
###end p 29
###begin p 30
###xml 346 350 346 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Heitjan1">[36]</xref>
###xml 352 356 352 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Little1">[37]</xref>
###xml 358 362 358 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Rubin1">[38]</xref>
###xml 83 86 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 119 125 <span type="species:ncbi:9606">person</span>
###xml 177 182 <span type="species:ncbi:9606">women</span>
As the study progressed, it became too expensive to continue to determine maternal HIV viral load for each mother ($40/person), resulting in incomplete data for the last 22% of women to enroll in the study. To address this issue, we investigated multiple imputation for the missing maternal viral loads, using Markov Chain Monte Carlo simulation [36], [37], [38]. To meet assumptions of normality for imputation models, MVL was log-transformed. Maternal CD4 count was found to be the only variable predictive of the missingness of MVL and of MVL values; thus, it was the only variable used in the imputation models. Of the genotyped individuals, subjects missing data on both log MVL and maternal CD4 count were excluded (2%), giving a total analysis sample size of 529. Imputation models were performed in STATA version 9 use ICE and MICOMBINE commands.
###end p 30
###begin title 31
Results
###end title 31
###begin title 32
Demographics
###end title 32
###begin p 33
###xml 222 229 222 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000838-t001">Table 1</xref>
###xml 4 11 <span type="species:ncbi:9606">infants</span>
###xml 15 18 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 28 33 <span type="species:ncbi:9606">women</span>
###xml 72 79 <span type="species:ncbi:9606">infants</span>
###xml 119 126 <span type="species:ncbi:9606">infants</span>
###xml 182 185 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 248 251 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
552 infants of HIV positive women provided a blood sample at birth. 381 infants were captured at 6 weeks (69%) and 335 infants were captured at 12 weeks (61%). A total of 101 became HIV positive over the follow-up period (Table 1). Log transformed HIV viral load was available for 402 mothers (mean = 4.57, SD = 0.72) and after imputation, an additional 127 values were obtained (overall mean = 4.67, SD = 0.66).
###end p 33
###begin title 34
###xml 14 17 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 28 35 <span type="species:ncbi:9606">infants</span>
Frequency and HIV status of infants captured through follow-up
###end title 34
###begin p 35
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 79 82 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 84 91 <span type="species:ncbi:9606">Infants</span>
###xml 137 144 <span type="species:ncbi:9606">infants</span>
HIV status at 6 weeks and at 12 weeks includes incident and prevalent cases of HIV. Infants who missed week 6 and returned at week 12 or infants present at week 6 but lost at week 12 were included in the summary.
###end p 35
###begin p 36
###xml 34 41 <span type="species:ncbi:9606">infants</span>
###xml 56 59 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Cumulative follow-up includes all infants who were ever HIV positive, regardless of loss to follow-up at one or more of the follow-up periods.
###end p 36
###begin title 37
Allelic Frequencies of Haplotypes and SNPs
###end title 37
###begin p 38
###xml 95 96 95 96 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 246 247 246 247 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 291 299 287 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000838-g002">Figure 2</xref>
###xml 358 366 354 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000838-g003">Figure 3</xref>
Among all eligible births for the study, the most common haplotypes were HHA, HHD, HHE, and HHF2, with allelic frequencies of 0.44, 0.34, 0.29 and 0.34, respectively. A lower frequency of haplotypes HHB (0.04) and HHF1 (0.09) was observed and HHG2 (bearing the Delta32 mutation) was absent (Figure 2). Allele frequencies for CCR2/CCR5 SNPs are summarized in Figure 3.
###end p 38
###begin p 39
###xml 246 253 246 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000838-t002">Table 2</xref>
Because of the rarity of some SNPs, the homozygous mutant genotypes and heterozygotes were combined into one category referred to as "carriers" of the mutation of interest, which was compared to non-carriers of the mutation in regression models (Table 2).
###end p 39
###begin title 40
Genotype Frequencies.
###end title 40
###begin p 41
###xml 150 158 150 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000838-g001">Figure 1</xref>
###xml 0 6 <span type="species:ncbi:9606">Infant</span>
Infant genotype frequencies were calculated for all eligible births. Wild type and variant alleles correspond to the evolutionary history outlined in Figure 1.
###end p 41
###begin title 42
Association between Haplotype/SNP and MTCT
###end title 42
###begin p 43
Non carriers of the haplotype or SNP were denoted as - - and carriers as ++/+-.
###end p 43
###begin p 44
The risk ratio (RR) was calculated from log linear regression, where non carriers (- -) were the referent. Maternal CD4 count, maternal age, and mode of delivery were not significantly associated with the SNPs/haplotypes or MTCT. Maternal viral load was significantly associated with MTCT but was not associated with SNPs or haplotypes. Therefore, these covariates were not included as confounders in the regression models.
###end p 44
###begin title 45
CCR5 polymorphism and MTCT
###end title 45
###begin p 46
###xml 198 199 198 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 397 401 397 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Kostrikis1">[18]</xref>
###xml 403 407 403 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Mangano1">[30]</xref>
###xml 409 416 409 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000838-t002">Table 2</xref>
###xml 784 791 784 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000838-t002">Table 2</xref>
In bivariate analyses, only HHB appeared to increase the risk of MTCT (RR = 1.96, 95% CI = 1.05, 3.66). This relationship was not statistically significant after adjusting for multiple comparisons (p = 0.24). No other statistically significant associations between individual haplotypes and MTCT were observed, although the direction of haplotype associations was consistent with previous reports [18], [30] (Table 2). No association between CCR2-64I and MTCT was observed, with an RR of approximately 1.0. A protective effect was observed for CCR5 -2733G, -2459G, -2135T, -2086G, and -1835T, and an increase in the risk of MTCT was observed for CCR5 -2554T and -2132T, which are consistent in direction with previous reports, but the associations were not statistically significant (Table 2).
###end p 46
###begin title 47
Effect of CCR5 polymorphisms on MTCT at different MVL strata
###end title 47
###begin p 48
###xml 113 117 113 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Ometto1">[31]</xref>
###xml 432 439 432 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000838-t003">Table 3</xref>
###xml 534 535 534 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 569 570 569 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 663 670 663 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000838-t004">Table 4</xref>
###xml 672 680 672 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000838-g004">Figure 4</xref>
In order to investigate whether MVL may be an effect measure modifier similar to that described in Ometto et al. [31], we examined whether the associations between SNPs and MTCT were homogeneous, after stratifying at the median value of log MVL (4.57, which corresponds to a viral load of 37,000 copies/mL). Stratification revealed that associations between CCR5 -2459G, CCR5 -2135T and MTCT were not homogeneous across MVL strata (Table 3). This was confirmed by the likelihood ratio Chi-Square (1 df) which was 3.83 for CCR5-2459G (p = 0.05) and 3.60 for CCR5-2135T (p = 0.05). Thus, both SNPs appear to be protective against MTCT at low MVL, but not high MVL (Table 4, Figure 4).
###end p 48
###begin title 49
Haplotype Frequencies.
###end title 49
###begin p 50
###xml 0 6 <span type="species:ncbi:9606">Infant</span>
Infant haplotype frequencies were calculated for all eligible births.
###end p 50
###begin title 51
Effect Measure Modification by MVL.
###end title 51
###begin p 52
Carriers of CCR5 -2459G and -2135T with low MVL were protected from MTCT, whereas carriers of -2459G and -2135T with high MVL demonstrated no change in susceptibility to MTCT.
###end p 52
###begin title 53
###xml 42 43 42 43 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table-fn" rid="nt105">*</xref>
Likelihood Ratio Test (LRT) of Homogeneity* of the association across MVL categories
###end title 53
###begin p 54
The LRT is the likelihood ratio Chi-Square with 1 degree of freedom, calculated as the deviance of the full model minus the deviance of the reduced model, where the models differed by inclusion of the interaction term.
###end p 54
###begin title 55
Risk ratio modification of MTCT by MVL
###end title 55
###begin p 56
Non carriers of the SNP were denoted as - - and carriers as ++/+-.
###end p 56
###begin p 57
The risk ratio (RR) was calculated from log linear regression, where non carriers (- -) were the referent.
###end p 57
###begin title 58
Discussion
###end title 58
###begin p 59
###xml 66 70 66 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Dean1">[10]</xref>
###xml 72 76 72 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Salkowitz2">[34]</xref>
###xml 78 82 78 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Thomas1">[39]</xref>
###xml 50 55 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CCR5 plays a major role in host susceptibility to HIV-1 infection [10], [34], [39]. In Blantyre, Malawi, among mothers with low viral loads, this study found a reduction in the risk of MTCT in babies bearing specific CCR5 variants. Reductions in the risk of MTCT were found for two linked CCR5 mutations, CCR5 -2459G and -2135T at low maternal viral loads.
###end p 59
###begin p 60
###xml 300 304 296 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Kostrikis1">[18]</xref>
###xml 306 310 302 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Gonzalez1">[27]</xref>
The frequencies of CCR5 variants observed in our study are similar to those reported in MTCT studies of African-American populations, in particular the absence of the Delta32 mutation, the very low frequency of HHB, and the relatively higher minor allele frequency of CCR5 -2459G, -2135T, and -2132T [18], [27].
###end p 60
###begin p 61
###xml 169 173 169 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Salkowitz1">[21]</xref>
###xml 175 179 175 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Kawamura1">[40]</xref>
###xml 124 127 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Carriage of CCR5 -2459G mutation has been associated with reduced density of CCR5 on CD14+ monocytes and lower levels of R5 HIV propagation when compared to CCR5 -2459A [21], [40]. Thus, as with the Delta32 mutation, reduced expression is correlated with protection against MTCT. The functional significance of -2459G is a key characteristic of this SNP in comparison to the other SNPs included in the haplotypes. Linkage disequilibrium between -2459G and -2135T may explain the similar findings for the two SNPs.
###end p 61
###begin p 62
###xml 178 182 178 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Kostrikis1">[18]</xref>
###xml 308 312 308 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Kostrikis1">[18]</xref>
###xml 415 419 415 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Mangano1">[30]</xref>
###xml 671 675 671 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-John1">[41]</xref>
###xml 406 414 <span type="species:ncbi:9606">children</span>
Our findings are somewhat different from 3 previous studies on MTCT. While we did not find a significant association between haplotype HHD homozygosity (bearing -2132T) and MTCT [18], like Kostrikis et al. we found a non-significant association suggesting that HHD was associated with increased risk of MTCT [18]. We did not observe an effect of HHE carriage or homozygosity on MTCT as seen in Argentinean children [30]. In contrast to John et al. who did not observe any influence of CCR5 gene polymorphism on MTCT in a Kenyan cohort, we observed a specific effect of reduced MTCT in association with CCR5 promoter polymorphisms characterized by reduced gene expression [41].
###end p 62
###begin p 63
###xml 204 210 <span type="species:ncbi:9606">infant</span>
There are four explanations for these discordant results. First, our study was the only one to account for effect measure modification by MVL. Second, our study was the only one to be conducted in mother-infant pairs treated with nevirapine. Third, all four studies were done in different populations where contributions from other genetic and environmental cofactors could occur. Finally, all of the studies comprise relatively small numbers and conduct multiple comparisons, and could be underpowered to find important associations.
###end p 63
###begin p 64
###xml 307 311 307 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Kwiek1">[42]</xref>
###xml 4 9 <span type="species:ncbi:9606">women</span>
###xml 72 75 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 284 289 <span type="species:ncbi:9606">child</span>
All women and their babies received nevirapine which would have reduced HIV inoculum size. Thus, nevirapine would likely cause an underestimate of the effect seen in the absence of treatment. There are many other determinants of transmission including obstetric factors and mother-to-child microtransfusion [42] that were not analyzed in our study but which should also have affected our findings in a non-differential manner.
###end p 64
###begin p 65
###xml 45 50 <span type="species:ncbi:9606">women</span>
Nearly all (98% at 6 weeks, 96% at 12 weeks) women in our study breast-fed. However, only 80% exclusively breast-fed at 6 weeks and only 46% exclusively breast-fed at 12 weeks. Exclusive breastfeeding at either 6 or 12 weeks was not associated with the main exposures (CCR5-2459G/-2135T) or the main outcome (MTCT) of interest (Pearson Chi-square p-values>0.05); thus was not viewed to be a potential confounder in the analysis.
###end p 65
###begin p 66
###xml 272 279 272 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000838-t005">Table 5</xref>
To address the loss to follow-up in our study, we conducted sensitivity analyses investigating the association between SNP and MTCT at different times of follow-up in the study. Our results showed that the effects of CCR5-2459G and -2135T are consistent across follow-up (Table 5).
###end p 66
###begin title 67
Sensitivity analyses for SNP association with MTCT at different time points of follow-up
###end title 67
###begin p 68
The risk ratio (RR) was calculated from log linear regression, where non carriers (- -) were the referent.
###end p 68
###begin p 69
###xml 473 480 473 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000838-t006">Table 6</xref>
To address the fact that we were missing 22% of MVL data, we conducted multiple imputation of MVL. Because only CD4count was used in the imputation models, this was actually single imputation. This approach was viewed to be more accurate than including variables that have no biological or statistical significance for predicting MVL. Our imputation results show that CCR5-2459G and -2135T are consistently associated with MTCT both overall and after dichotomizing by MVL (Table 6). Although a complete dataset is preferable, the missing data in our study did not appear to be problematic for accurate interpretation of results.
###end p 69
###begin title 70
Imputation Results for 5 imputations (N = 529 per imputation)
###end title 70
###begin p 71
The risk ratio (RR) was calculated from log linear regression, where non carriers (- -) were the referent.
###end p 71
###begin p 72
The generalizability and replicability of our study may be limited because the median value of log MVL (4.57) was used to create the dichotomous variable. We could have used a value of 4, which corresponds to a viral load of 10,000 copies/microL, a more commonly used value in the literature. However, our cut point was determined as a key component to a priori set hypotheses.
###end p 72
###begin p 73
Because log-linear regression models using imputed data are considered to be experimental in STATA (version 9), we presented odds ratios from logistic regression models to estimate risk ratios. This may have biased our results away from the null, as odds ratios from logistic regression generally overestimate the relative risks from log-linear regression. However, we compared the results of the experimental log-linear and logistic imputation models and found similar results (data not shown).
###end p 73
###begin p 74
###xml 678 682 678 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Lederman1">[43]</xref>
###xml 1017 1021 1017 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000838-Princen1">[44]</xref>
###xml 52 58 <span type="species:ncbi:9606">infant</span>
###xml 141 147 <span type="species:ncbi:9606">infant</span>
###xml 227 234 <span type="species:ncbi:9606">infants</span>
###xml 1252 1257 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In conclusion, this study characterized the role of infant CCR5 polymorphisms in susceptibility to MTCT in nevirapine-treated African mother-infant pairs. Our results suggest a protective effect of CCR5 -2459G and -2135T among infants of mothers with low maternal viral load, which might be due to a reduction in the expression of the CCR5 receptor. The influence of MVL on this effect suggests that there may be a threshold in the ratio of virus to receptor above which changes in the receptor concentration have no effect on viral infectivity. Although our study was not of heterosexual transmission, it may have implications for microbicides designed to block access to CCR5 [43]. If a threshold exists for receptor access by virus, there will also be a threshold for blocking receptor access by virus. Ensuring that a CCR5-blocking microbicide is present at a concentration that will not be overwhelmed by viral load is critical. These findings are also applicable to antiretroviral drugs such as CCR5 inhibitors [44] and chemoprophylaxis in high risk populations, where delivery mechanisms differ from those of vaginal microbicides. Continuing studies on the genetics of MTCT will provide better insight into the pathophysiology and prevention of HIV-1 MTCT with potential applications to other modes of transmission.
###end p 74
###begin title 75
References
###end title 75
###begin article-title 76
AIDS Epidemic Update.
###end article-title 76
###begin article-title 77
###xml 35 40 <span type="species:ncbi:9606">child</span>
###xml 57 85 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Estimating the timing of mother-to-child transmission of human immunodeficiency virus in a breast-feeding population in Kinshasa, Zaire.
###end article-title 77
###begin article-title 78
###xml 30 35 <span type="species:ncbi:9606">child</span>
###xml 36 71 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 73 78 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 123 126 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. The HIV Infection in Newborns French Collaborative Study Group.
###end article-title 78
###begin article-title 79
###xml 26 29 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Genetics of resistance to HIV infection: Role of co-receptors and co-receptor ligands.
###end article-title 79
###begin article-title 80
###xml 75 80 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.
###end article-title 80
###begin article-title 81
###xml 62 67 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Identification of a major co-receptor for primary isolates of HIV-1.
###end article-title 81
###begin article-title 82
###xml 22 27 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.
###end article-title 82
###begin article-title 83
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.
###end article-title 83
###begin article-title 84
###xml 93 98 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1.
###end article-title 84
###begin article-title 85
###xml 23 28 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.
###end article-title 85
###begin article-title 86
###xml 36 41 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.
###end article-title 86
###begin article-title 87
###xml 21 26 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 102 107 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.
###end article-title 87
###begin article-title 88
###xml 14 19 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.
###end article-title 88
###begin article-title 89
###xml 24 29 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk.
###end article-title 89
###begin article-title 90
###xml 55 60 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32.
###end article-title 90
###begin article-title 91
###xml 83 88 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CCR5 promoter polymorphisms, CCR5 59029A and CCR5 59353C, are under represented in HIV-1-infected long-term non-progressors. The Australian Long-Term Non-Progressor Study Group.
###end article-title 91
###begin article-title 92
###xml 53 58 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Adverse effect of the CCR5 promoter -2459A allele on HIV-1 disease progression.
###end article-title 92
###begin article-title 93
###xml 113 148 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 169 176 <span type="species:ncbi:9606">infants</span>
A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants.
###end article-title 93
###begin article-title 94
###xml 31 36 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS).
###end article-title 94
###begin article-title 95
###xml 94 129 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 131 136 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 160 165 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression.
###end article-title 95
###begin article-title 96
###xml 79 84 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro.
###end article-title 96
###begin article-title 97
###xml 129 164 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission.
###end article-title 97
###begin article-title 98
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation.
###end article-title 98
###begin article-title 99
###xml 52 55 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Easterbrook University of Nairobi Collaboration for HIV Research.
###end article-title 99
###begin article-title 100
###xml 37 65 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Chemokine receptor polymorphisms and human immunodeficiency virus disease progression.
###end article-title 100
###begin article-title 101
###xml 126 129 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Chemokine receptor CCR2b 64I polymorphism and its relation to CD4 T-cell counts and disease progression in a Danish cohort of HIV-infected individuals. Copenhagen AIDS cohort.
###end article-title 101
###begin article-title 102
###xml 14 19 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes.
###end article-title 102
###begin article-title 103
###xml 77 105 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 107 110 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 140 145 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
No evidence for an effect of the CCR5 delta32/+ and CCR2b 64I/+ mutations on human immunodeficiency virus (HIV)-1 disease progression among HIV-1-infected injecting drug users.
###end article-title 103
###begin article-title 104
###xml 13 18 <span type="species:ncbi:9606">human</span>
###xml 27 32 <span type="species:ncbi:9606">human</span>
###xml 279 284 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 289 318 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
Evolution of human and non-human primate CC chemokine receptor 5 gene and mRNA. Potential roles for haplotype and mRNA diversity, differential haplotype-specific transcriptional activity, and altered transcription factor binding to polymorphic nucleotides in the pathogenesis of HIV-1 and simian immunodeficiency virus.
###end article-title 104
###begin article-title 105
###xml 129 137 <span type="species:ncbi:9606">children</span>
###xml 161 189 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus.
###end article-title 105
###begin article-title 106
###xml 21 26 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 90 95 <span type="species:ncbi:9606">child</span>
###xml 96 101 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Co-receptor usage of HIV-1 primary isolates, viral burden, and CCR5 genotype in mother-to-child HIV-1 transmission.
###end article-title 106
###begin article-title 107
###xml 75 80 <span type="species:ncbi:9606">child</span>
###xml 97 100 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Maternal syphilis infection is associated with increased risk of mother-to-child transmission of HIV in Malawi.
###end article-title 107
###begin article-title 108
###xml 14 35 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 72 77 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 118 123 <span type="species:ncbi:9606">women</span>
The effect of Plasmodium falciparum malaria on peripheral and placental HIV-1 RNA concentrations in pregnant Malawian women.
###end article-title 108
###begin article-title 109
###xml 30 35 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Characterization of high-risk HIV-1 seronegative hemophiliacs.
###end article-title 109
###begin article-title 110
###xml 131 134 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Multiplex Ligase Detection Reaction-based Genotyping Analysis of CCR2-CCR5 Polymorphism Improves Large-scale Population Studies of HIV Co-receptors.:
###end article-title 110
###begin article-title 111
Annotation: what can be done about missing data? Approaches to imputation.
###end article-title 111
###begin article-title 112
Statistical Analysis with Missing Data.
###end article-title 112
###begin article-title 113
Multiple Imputation for Nonresponse n Surveys.
###end article-title 113
###begin article-title 114
###xml 64 67 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 81 84 <span type="species:ncbi:9606">men</span>
###xml 103 106 <span type="species:ncbi:9606">men</span>
CCR5 expression and duration of high risk sexual activity among HIV-seronegative men who have sex with men.
###end article-title 114
###begin article-title 115
###xml 3 6 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms.
###end article-title 115
###begin article-title 116
###xml 50 85 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
CCR5 promoter polymorphisms in a Kenyan perinatal human immunodeficiency virus type 1 cohort: association with increased 2-year maternal mortality.
###end article-title 116
###begin article-title 117
###xml 37 42 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 53 58 <span type="species:ncbi:9606">child</span>
Maternal-fetal microtransfusions and HIV-1 mother-to-child transmission in Malawi.
###end article-title 117
###begin article-title 118
###xml 43 58 <span type="species:ncbi:9544">rhesus macaques</span>
Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5.
###end article-title 118
###begin article-title 119
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 48 51 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV chemokine receptor inhibitors as novel anti-HIV drugs.
###end article-title 119
###begin p 120
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 120
###begin p 121
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
###xml 269 274 <span type="species:ncbi:9606">women</span>
###xml 345 348 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Funding: This work was supported by NIH grant # AI 49084 (SM), 5P01AI051649-05 (PZ), the NIH-FIC grant # 5 D43 TW00908 and the Center for AIDS Research at the University of North Carolina. SJR is a Wellcome Trust Senior Overseas Fellow in Biomedical Sciences. Pregnant women in this study were given nevirapine provided by Global Strategies for HIV Prevention. None of the sponsors had any input in the manuscript.
###end p 121

